John W. Walsh Alpha-1 Home Infusion Act of 2022

Bill 117 HR 7346, also known as the John W. Walsh Alpha-1 Home Infusion Act of 2022, aims to improve access to home infusion therapy for individuals with Alpha-1 Antitrypsin Deficiency. This genetic disorder can lead to serious lung and liver complications, and home infusion therapy can help manage symptoms and improve quality of life for patients.

The bill proposes several key provisions to achieve this goal. First, it calls for the establishment of a demonstration program to provide home infusion therapy services to Alpha-1 patients. This program would be implemented by the Centers for Medicare and Medicaid Services (CMS) and would evaluate the effectiveness of home infusion therapy in improving patient outcomes and reducing healthcare costs.

Additionally, the bill seeks to increase awareness and education about Alpha-1 Antitrypsin Deficiency among healthcare providers and the general public. This includes developing educational materials and resources to help patients and their families better understand the condition and available treatment options. Furthermore, the bill aims to address barriers to accessing home infusion therapy, such as reimbursement issues and limited provider networks. It calls for the development of guidelines and standards for home infusion services, as well as increased oversight and monitoring to ensure quality and safety. Overall, the John W. Walsh Alpha-1 Home Infusion Act of 2022 is a bipartisan effort to improve care and support for individuals with Alpha-1 Antitrypsin Deficiency. By expanding access to home infusion therapy and increasing awareness of the condition, this bill has the potential to make a meaningful impact on the lives of patients and their families.